FOI release

Public Assessment Report (PAR) – PL 20416/0010–0011 (For MAH Records)

Some or all of the information requested was not provided because we didn't hold it.

Case reference FOI2026/00213

Received 26 February 2026

Published 14 April 2026

Request

I am writing on behalf of Crescent Pharma Limited, Marketing Authorisation Holder for Amoxicillin 125mg/5ml Oral Suspension and Amoxicillin 250mg/5ml Oral Suspension (PL 20416/0010-0011). We kindly request a copy of the Public Assessment Report (PAR) for the above-mentioned Marketing Authorisation. The requested documentation is required for our internal regulatory records and product lifecycle management purposes. We confirm that Crescent Pharma Limited is the current MAH for these licences. Should you require any formal confirmation, authorisation documentation, or completion of a specific request form, please let us know. We would appreciate confirmation of receipt of this request and details of any applicable process or timeline for provision of the PAR.

Response

See attached

Documents

• FOI2026_00213 (redacted).pdf (566.0 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.